Polygenic resilience scores capture protective genetic effects for Alzheimer's disease
- PMID: 35879306
- PMCID: PMC9314356
- DOI: 10.1038/s41398-022-02055-0
Polygenic resilience scores capture protective genetic effects for Alzheimer's disease
Abstract
Polygenic risk scores (PRSs) can boost risk prediction in late-onset Alzheimer's disease (LOAD) beyond apolipoprotein E (APOE) but have not been leveraged to identify genetic resilience factors. Here, we sought to identify resilience-conferring common genetic variants in (1) unaffected individuals having high PRSs for LOAD, and (2) unaffected APOE-ε4 carriers also having high PRSs for LOAD. We used genome-wide association study (GWAS) to contrast "resilient" unaffected individuals at the highest genetic risk for LOAD with LOAD cases at comparable risk. From GWAS results, we constructed polygenic resilience scores to aggregate the addictive contributions of risk-orthogonal common variants that promote resilience to LOAD. Replication of resilience scores was undertaken in eight independent studies. We successfully replicated two polygenic resilience scores that reduce genetic risk penetrance for LOAD. We also showed that polygenic resilience scores positively correlate with polygenic risk scores in unaffected individuals, perhaps aiding in staving off disease. Our findings align with the hypothesis that a combination of risk-independent common variants mediates resilience to LOAD by moderating genetic disease risk.
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
OAA is a consultant to HealthLytix. SVF in the past year, received income, potential income, travel expenses continuing education support and/or research support from Aardvark, Akili, Genomind, Ironshore, KemPharm/Corium, Noven, Ondosis, Otsuka, Rhodes, Supernus, Takeda, Tris, and Vallon. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Alcobra, Arbor, Aveksham, CogCubed, Eli Lilly, Enzymotec, Impact, Janssen, Lundbeck/Takeda, McNeil, NeuroLifeSciences, Neurovance, Novartis, Pfizer, Shire, and Sunovion. He also receives royalties from books published by Guilford Press:
Figures



References
-
- Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2021;17:327–406. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MR/K013041/1/MRC_/Medical Research Council/United Kingdom
- R01AG054002/AG/NIA NIH HHS/United States
- R01 AG064955/AG/NIA NIH HHS/United States
- R01AG064955/AG/NIA NIH HHS/United States
- G0300429/MRC_/Medical Research Council/United Kingdom
- R01 AG054002/AG/NIA NIH HHS/United States
- R01 AG060470/AG/NIA NIH HHS/United States
- MC_PC_17112/MRC_/Medical Research Council/United Kingdom
- R01 AG076838/AG/NIA NIH HHS/United States
- MR/T04604X/1/MRC_/Medical Research Council/United Kingdom
- G0902227/MRC_/Medical Research Council/United Kingdom
- R01 MH116037/MH/NIMH NIH HHS/United States
- MR/L501517/1/MRC_/Medical Research Council/United Kingdom
- R01 HL105756/HL/NHLBI NIH HHS/United States
- MR/L023784/2/MRC_/Medical Research Council/United Kingdom
- MR/L010305/1/MRC_/Medical Research Council/United Kingdom
- U01 AR076092/AR/NIAMS NIH HHS/United States
- R01 AG050595/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous